Omnitek Q2 sales surge; back to profit but faces cash crunch, going-concern warning

Omnitek Engineering Corp. (OTCMKTS: OMTK)

Quick read: Q2 2025 shows strong revenue growth and a return to reported net income, but liquidity, related‑party obligations, large inventory reserves and a going‑concern/internal control warning remain major risks.

Snapshot - key facts & statistics

- Revenues (3 months ended Jun 30, 2025): $605,407 vs $266,971 (Q2 2024).

- Revenues (6 months ended Jun 30, 2025): $965,153 vs $504,047 (H1 2024) - +92% YoY (six months).

- Gross margin (Q2 2025): $221,751 (37% of sales); Gross margin (H1 2025): $362,719 (38%).

- Net profit (Q2 2025): $125,853 (reported $0.01 per share); Net profit (H1 2025): $99,193 (reported $0.00 per share).

- Other income (Q2): $88,237 - a large positive item that materially drove profit.

- Cash (Jun 30, 2025): $32,636 (down from $104,445 at 12/31/24).

- Net inventories (Jun 30, 2025): $325,861 (gross inventory $1,351,978 with allowance for obsolete inventory $1,026,117).

- Customer deposits: $598,327 (down from $845,272 at 12/31/24).

- Current liabilities: $1,921,481; Total liabilities: $2,120,481.

- Working capital: negative $1,209,105 (current assets $712,376 vs current liabilities $1,921,481).

- Stockholders' deficit: $(1,244,489); accumulated deficit: $(21,928,291).

- Cash used in operating activities (H1 2025): $(128,809).

- Accrued management compensation due: $635,734.

- Notes payable - related party: $101,940 (up from $44,940); Convertible note (related party) still $10,000.

- Weighted average shares outstanding: 21,948,091.

Positives

- Strong top‑line momentum: revenue jumped materially vs prior year (Q2 +56% ; H1 +92%).

- Returned to reported net income in both the quarter and H1 after prior losses.

- Gross margin held near high‑30% levels despite higher COGS - suggests decent product margin on sales mix (international/components heavy).

- Operating expenses were largely stable year‑over‑year (G&A and R&D roughly flat), indicating some operating leverage.

Negatives / Risks

- Liquidity is strained: only $32,636 cash on hand and negative working capital of $1.21M - likely to require external funding before long.

- Operating cash flow is negative: $(128,809) in H1 despite accounting net income - working capital swings and deposits reduced cash.

- Large inventory reserves: $1.03M allowance leaves net inventory of $325,861 but signals slow/obsolete stock risk and potential write‑downs.

- Heavy related‑party exposure: $101,940 notes payable to CEO, $13,089 AR from a related party, and $635,734 accrued management compensation - concentration and governance concerns.

- Profitability boosted by a one large "Other income" item ($88,237). If non‑recurring, underlying operating strength is weaker.

- Material uncertainty: management discloses substantial doubt about going concern for the next 12 months.

- Internal control weakness: disclosure controls not effective due to lack of segregation of duties - higher risk of misstatements.

- Legal exposure: cross‑complaint pending; trial set for December 8, 2025 (potential cost/uncertainty).

Takeaway - what's happening inside the company

- Omnitek is selling more (especially internationally and in components), producing better GAAP results and margins, but the reported profits rely significantly on non‑operating/other income and were not converted into operating cash inflows.

- The balance sheet shows structural weaknesses: thin cash, negative working capital, large obsolete inventory reserve, sizable accrued compensation and related‑party financing. Management acknowledges going‑concern risk and a material weakness in controls.

- Near term story: growth in sales and margins is encouraging, but the company likely needs external capital or improved cash conversion to sustain operations and remove going‑concern uncertainty. Monitor cash, customer deposits, any recurring nature of "other income", related‑party funding and progress on the legal matter.

Document source: Omnitek Engineering Corp. Form 10‑Q for period ended June 30, 2025 (financial statements and MD&A).